2017 Janssen U.S. Transparency Report
Our second annual Janssen U.S. Transparency Report reflects our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines, and help people who need our medicines get access to them.

Jennifer Taubert Discusses This Year's U.S. Transparency Report

2017 Janssen U.S. Transparency Report: Jennifer Taubert

As our second annual Janssen U.S. Transparency Report shows, in 2017 the net price of our medicines in the U.S. decreased while we increased to $7.9 billion our investment in discovering and developing transformational medicines for patients facing some of the world’s most challenging diseases. Our Report demonstrates our commitment to responsible business practices that put patients first, including how we invest our resources, price our medicines, and help people who need Janssen medicines get access to them.

2017
JANSSEN U.S. TRANSPARENCY REPORT
By the Numbers: Janssen in 2017
$7.9 B
Invested in research and development1
$15 B
Approximate total discounts and rebates
-4.6%
Average net price change5
We hope that by providing even more transparency into how we operate, we can continue to make progress toward a more results-based health care system that meets the needs of patients today and patients tomorrow.
Jennifer Taubert & Anastasia G. Daifotis
More Resources